{"nctId":"NCT02455336","briefTitle":"Fenofibrate Treatment in SCI","startDateStruct":{"date":"2015-05-18","type":"ACTUAL"},"conditions":["Spinal Cord Injury","Dyslipidemia"],"count":23,"armGroups":[{"label":"Fenofibrate","type":"EXPERIMENTAL","interventionNames":["Drug: Fenofibrate"]},{"label":"No Intervention","type":"OTHER","interventionNames":["Other: No intervention"]}],"interventions":[{"name":"Fenofibrate","otherNames":[]},{"name":"No intervention","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, age 21 to 69;\n* Chronic (e.g., duration of injury at least 6 months), stable SCI (regardless of level of neurological lesion);\n* American Spinal Injury Association Impairment Scale (AIS) designation of A, B or C; and\n* TG concentration 135 mg/dl (paraplegia) or 115 mg/dl (tetraplegia).\n\nExclusion Criteria:\n\n* Acute illness or infection;\n* Reduced kidney function (by glomerular filtration rate (GFR \\<60 ml/min) or liver function tests (LFTs 2.5 standard deviations above the upper limit of normal);\n* Current pharmacological treatment with: HMG-CoA reductase inhibitors (statins), or any other hypolipidemic agent; anti-coagulant therapy; cyclosporine; or any other medications known to effect the TG concentration (i.e., -blockers, thiazides or estrogen);\n* Hypersensitivity to fenofibrate;\n* Existing diagnosis of atherosclerosis, congestive heart failure, or recent history of myocardial infarction (i.e., 12 months);\n* Pregnancy or women who may become pregnant during the course of the study, or those who are nursing;\n* Diminished mental capacity; and\n* Inability or unwillingness of subject to provide informed consent.\n* Existing diagnosis of diabetes mellitus, or the results from screening blood tests indicate that diabetes mellitus is present (and perhaps undiagnosed); laboratory thresholds for exclusion will be as follows: HbA1C 6.5% and fasting plasma glucose is \\>126 mg/dl.","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","maximumAge":"69 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Triglyceride Concentration (Percent Change From Baseline)","description":"To determine the efficacy of fenofibrate monotherapy after 2 months of treatment to improve the lipoprotein profile; a successful response will be defined as a 25% reduction in the serum TG concentration at 2 months.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40","spread":"12"},{"groupId":"OG001","value":"-2","spread":"16"}]}]}]},{"type":"SECONDARY","title":"Triglyceride Concentration (Percent Change From Baseline)","description":"To determine the efficacy of fenofibrate monotherapy to lower TG concentration at 4 months of treatment, when the peak therapeutic efficacy to drug treatment has been reported to occur.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-40","spread":"20"},{"groupId":"OG001","value":"7","spread":"14"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Adverse Event Profile","description":"Documentation and description of adverse events will be obtained in subjects who have received drug treatment compared to events occurring in the control group.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Elevated liver enzymes","Gastrointestinal discomfort"]}}}